Stay updated on NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer

Sign up to get notified when there's something new on the NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer page.
Latest website image capture
Clouds background image

Latest updates to the NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T19:45:27.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:22:06.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:09:11.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:24:53.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on pembrolizumab for non-small cell lung cancer, while adding new identifiers and collaborators.
    Difference
    37%
    Check dated 2025-04-16T10:56:50.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The webpage has been updated to include new endpoints for tumor response evaluation and survival statistics, while removing previous data on adverse events and clinical response rates.
    Difference
    29%
    Check dated 2025-04-09T05:29:09.000Z thumbnail image

Stay in the know with updates to NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer

Enter your email address, and we'll notify you when there's something new on the NEOMUN Trial: Anti-PD-1 in Resectable Lung Cancer page.